EGRX — Eagle Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Eagle Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	213	196	188	172	317
Cost of Revenue
Gross Profit	151	135	142	129	222
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	177	174	155	169	241
Operating Profit	36.6	21.8	33	2.77	76
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	34	22	22.7	-4.55	61.4
Provision for Income Taxes
Net Income After Taxes	31.9	14.3	12	-8.63	35.6
Net Income Before Extraordinary Items
Net Income	31.9	14.3	12	-8.63	35.6
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	31.9	14.3	12	-8.63	35.6
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.74	1.01	0.871	-0.661	3.9